Sugi Predict

Sugi Predict / Compounds / SCHEMBL1284882

SCHEMBL1284882

SCHEMBL1284882

Nc1cnn(CCN2CCOCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 1/20 0.43
▸ PIM3 Q86V86 1/20 0.43
▸ PIM2 Q9P1W9 1/20 0.43
▸ IKBKE Q14164 1/20 0.42
▸ TBK1 Q9UHD2 1/20 0.42
▸ PLAU P00749 1/20 0.41
▸ CYP11B2 P19099 1/20 0.40
▸ KEAP1 Q14145 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MAP4K4 O95819 1/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ JAK2 O60674 3/20 0.39
▸ JAK1 P23458 2/20 0.39
▸ TYK2 P29597 2/20 0.39
▸ JAK3 P52333 2/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ STAT3 P40763 1/20 0.39
▸ ALOX5AP P20292 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL23212528 0.98 PIM1 (0.42) PIM1PIM3PIM2IKBKETBK1
SCHEMBL1662821 0.92 MAPT (0.45) PIM1PIM3PIM2IKBKETBK1
SCHEMBL1703040 0.86 SIGMAR1 (0.41) PLAUMAPTJAK2JAK1TYK2
SCHEMBL1703940 0.84 SIGMAR1 (0.43) PLAUMAPTJAK2JAK1TYK2
SCHEMBL522038 0.83 LMNA (0.42) MAPTLMNAFGFR3
Isophthalic Acid SCHEMBL27776777 0.82 KDM5A (0.50) IKBKETBK1CYP11B2SMN1; SMN2MAPT
SCHEMBL14320448 0.82 MAP4K4 (0.53) PIM1PIM3PIM2IKBKETBK1
SCHEMBL15651238 0.81 PAICS (0.41) PIM1PIM3PIM2SMN1; SMN2MAPT
SCHEMBL17076772 0.81 MAPT (0.41) SMN1; SMN2MAPTLMNA
SCHEMBL28104942 0.81 RAB9A (0.44) IKBKETBK1PLAUCYP11B2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630530-B2 FGFR inhibitor compound and use thereof HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2026-05-19 — — US disclosed
EP-4656249-A2 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR Daewoong Pharmaceutical Co., Ltd. (KR) 2025-12-03 — — EP disclosed
EP-4067354-B1 NOVEL TRIAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DAEWOONG PHARMACEUTICAL CO LTD (KR) 2025-10-22 — — EP disclosed
CN-119751439-A ATF6 modulators and uses thereof 阿尔托斯实验室公司 2025-04-04 — — CN disclosed
CN-115087656-B ATF6 modulators and uses thereof 阿尔托斯实验室公司 2024-12-13 — — CN disclosed
EP-4186894-B1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) 2024-12-04 — — EP disclosed
EP-3478687-B1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR DAEWOONG PHARMACEUTICAL CO LTD (KR) 2024-03-20 — — EP disclosed
US-20230399312-A1 SUBSTITUTED PYRIMIDINES AND METHODS OF USE THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-12-14 — — US disclosed
CN-114728963-B Novel triazolopyridine derivatives and pharmaceutical compositions comprising the same 株式会社大熊制药 2023-10-31 — — CN disclosed
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-22 — — US disclosed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 — — US disclosed
WO-2010138576-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 — — WO disclosed
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity ABBOTT LABORATORIES (US) 2010-12-02 — — US disclosed
WO-2010100431-A1 PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-09-10 — — WO disclosed
WO-2010100431-A1 PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-09-10 — — WO disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 — — US disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 — — US disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 — — US disclosed
WO-2009122180-A1 PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES MEDICAL RESEARCH COUNCIL (GB) 2009-10-08 — — WO disclosed
WO-2009122180-A1 PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES MEDICAL RESEARCH COUNCIL (GB) 2009-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES AURKA, AURKC, AURKB PIM1 750/4885PIM3 698/4885PIM2 787/4885
US-20100056524-A1 Compound NR3C2, NR3C1, NR2E3 PIM1 2512/4885PIM3 2002/4885PIM2 2483/4885
US-12630530-B2 FGFR inhibitor compound and use thereof FGFR3, FGFR1, FGFR4 PIM1 906/4885PIM3 926/4885PIM2 982/4885
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity IGF1R, CDK2, TK1 PIM1 321/4885PIM3 455/4885PIM2 351/4885
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF FGFR3, FGFR1, FGFR4 PIM1 379/4885PIM3 627/4885PIM2 551/4885
US-20230399312-A1 SUBSTITUTED PYRIMIDINES AND METHODS OF USE ALK, TYMP, ENTPD5 PIM1 965/4885PIM3 939/4885PIM2 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.